Focal RT with three 8 Gy fractions given every other day, pembrolizumab and CDX-301 (a dendritic cell and hematopoietic stem cell stimulator) together with neoadjuvant hormonal therapy for stage II-III HER+ and HER2− BC patients, are under investigation in a randomized phase II study (NCT03804944) [76]. Here, ERBB2 is linked to breast cancer.